Skip to main content
Neuro-Oncology logoLink to Neuro-Oncology
. 2023 Jun 12;25(Suppl 1):i40–i41. doi: 10.1093/neuonc/noad073.158

HGG-09. GLIOMATOSIS CEREBRI IN CHILDREN: A POOR PROGNOSTIC, HIGHLY INFILTRATIVE PHENOTYPE OF DIFFUSE PEDIATRIC HIGH-GRADE GLIOMAS WITH DISTINCT MOLECULAR FEATURES

Gunther Nussbaumer 1, Martin Benesch 2, Yura Grabovska 3, Alan Mackay 4, David Castel 5,6, Jacques Grill 7,8, Marta M Alonso Roldán 9, Manila Antonelli 10, Simon Bailey 11, Joshua N Baugh 12, Alberto Broniscer 13, Shauna Crampsie 14, Natacha Entz-Werle 15,16, Matthias Eyrich 17, Maria L Garre 18, Nicolas U Gerber 19, Felice Giangaspero 20, Maria J Gil-da-Costa 21, Darren Hargrave 22, Peter Hauser 23, Ulrich Herrlinger 24, Marion Hoffmann 25, Sandra Jacobs 26, Michael Karremann 27, Antonis Kattamis 28, Rejin Kebudi 29, Robert Kwiecien 30, Maura Massimino 31, Angela Mastronuzzi 32, Virve Pentikainen 33, Thomas Perwein 34, Stefan M Pfister 35,36, Torsten Pietsch 37, Dominik Sturm 38,39, David Sumerauer 40, Dannis van Vuurden 41, André O von Bueren 42, Pascale Varlet 43, Sophie E M Veldhuijzen van Zanten 44, Maria Vinci 45, Monika Warmuth-Metz 46, Pieter Wesseling 47,48, Maria Wiese 49, Josef Zamecnik 50, Andrés Morales La Madrid 51, Brigitte Bison 52, Gerrit H Gielen 53, David T W Jones 54,55, Chris Jones 56, Christof M Kramm 57
PMCID: PMC10260055

Abstract

Gliomatosis cerebri (GC), a radiologically defined highly infiltrating supratentorial glioma, is no longer considered a distinct entity since the 2016 WHO classification for tumors of the central nervous system (CNS). So far, neither prognostic factors, nor molecular GC-associated features have been established. We conducted a multinational retrospective study of 104 children and adolescents with GC providing comprehensive radiological, clinical and (epi-)genetic characterization. Within a median follow-up of 15.5 months (range, 2.3–138.8), 93 patients (89.4%) had died, four (3.8%) were lost to follow-up and seven (6.8%) were alive with stable/progressive disease. Median progression-free- (PFS) and overall survival (OS) were 8.6 months (interquartile range, 4.3–14.0) and 15.5 months (10.9–27.7), respectively. Available histopathological grading correlated significantly with median OS: CNS-WHO grade II: 47.8 months (25.2–55.7); grade III: 15.9 months (11.4–26.3); grade IV: 10.4 months (8.8–14.4). In GC with high-grade features, radiochemotherapy achieved longest PFS (median 9.6 months [5.7–14.0]). According to methylation profiling [n=49] and exome-sequencing [n=45], most cases were considered as IDH-/H3-wildtype gliomas (n=32/52, 61.5%) enriched with the subclasses pedHGG_RTK2A/B (n=19), pedHGG_A/B (n=6) and pedHGG_MYCN (n=5), but exhibited only one pedHGG_RTK1A/B/C case. Within the IDH-/H3-wildtype gliomas, EGFR-alterations were most common (n=10). Expected genetic alterations of unselected hemispheric pedHGG affecting CDKN2A/B, ATRX or PDGFRA were virtually absent. Additionally, we observed structural aberrations in chromosome 6 comprising complex genomic rearrangements, large areas of loss, or even gain/amplification at similar breakpoints in 16/49 cases (32.7%). We assembled the largest pediatric GC cohort providing evidence that GC may have a strong predilection to arise on the background of specific molecular features (pedHGG_RTK2A/B, pedHGG_A/B and pedHGG_MYCN; EGFR- and chromosome 6-alterations). Taken together, these findings expand on the current understanding of GC and provide insight into disease biology of extensively infiltrating gliomas in children.


Articles from Neuro-Oncology are provided here courtesy of Society for Neuro-Oncology and Oxford University Press

RESOURCES